Onset/flare of psoriasis following the
            <scp>ChAdOx1 nCoV</scp>
            ‐19 Corona virus vaccine (
            <scp>Oxford‐AstraZeneca</scp>
            /Covishield): Report of two cases

Nagrani, Prateek; Jindal, Rashmi; Goyal, Dikshita

doi:10.1111/dth.15085

Cited by 26 publications

(42 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, most reactions were mild-moderate in severity and self-limiting, but some required treatment mostly with topical/systemic steroids or oral antihistamines [ 6 ]. On the other hand, there were few reported cases of flare of psoriasis [ 7 ], Erythema nodosum, zoster duplex reactivation and pityriasis rosea as possible cutaneous adverse effects of Oxford-AstraZeneca COVID-19 vaccine [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine

Alhammad¹,

Milibary²,

Baghdadi³

et al. 2022

Cureus

View full text Add to dashboard Cite

Morbilliform eruption typically implies a maculopapular rash of acute onset. Drugs are the predominant cause of this cutaneous reaction in adults, followed by infectious exanthems and some rheumatological diseases. In this article, we report on the clinical and histopathological features of generalized pruritic morbilliform eruption in a 28-year-old female following her second dose of Oxford/AstraZeneca COVID-19 vaccine. The reaction started 12 hours after receiving the vaccine with no other identifiable cause. The patient had no improvement with IV antihistamine received in the emergency department. Afterward, she showed marked improvement after receiving a short course of oral corticosteroids along with topical corticosteroid and oral antihistamine. To the best of our knowledge, we hypothesize that the basic immunological mechanism is the cause behind COVID-19-vaccine-related morbilliform eruption. Therefore, physicians should be aware of the possible adverse reactions associated with COVID-19 vaccines, such as morbilliform eruptions and other cutaneous manifestations.

show abstract

Section: Discussionmentioning

confidence: 99%

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine

Alhammad¹,

Milibary²,

Baghdadi³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…GPP outbreaks following influenza, hepatitis B vaccination and intravesical BCG immunotherapy have been reported [8][9][10][11][12][13] (Table 1). Flares after COVID19 vaccination have included one case after COVID-19-Pfizer-BioNTechBNT16B2b2mRNA and two cases after ChAdOx1nCoV-19 vaccine (plaque lesions) and one case after Sinovac vaccines (GPP) [5][6][7] . Our patient is the first report of a pustular outbreak following the ChAdOx1nCoV-19 vaccine (Table 2).…”

Section: Discussionmentioning

confidence: 99%

“…In the specific context of generalized pustular psoriasis (GPP), few case reports describing pustular outbreaks following vaccination have been reported and only two, including this case, described flares after COVID19vaccination [1][2][3][4] , specifically Sinovac and ChAdOx1nCoV-19 vaccines. In addition, there is description of plaque psoriasis flare after COVID-19-Pfizer-BioNTechBNT16B2b2mRNA and ChAdOx1nCoV-19 vaccines [5][6][7] . To date, no case reports have been published describing the exacerbation of pustular psoriasis after vaccination with ChAdOx1nCoV-19.…”

Section: Introductionmentioning

confidence: 99%

Generalized Pustular Psoriasis Triggered by ChAdOx1nCoV-19 Vaccine: a case report

Salviano

Breda

Romiti

et al. 2022

Preprint

View full text Add to dashboard Cite

“…Nevertheless, the side effects of the Oxford-AstraZeneca vaccine cannot be overlooked, such as thrombotic thrombocytopenia (197)(198)(199) that usually occurred in young population, thromboembolism (191,200), thrombotic adverse (201), skin rash (202) or necrosis (203), psoriasis (204), etc., where most of AEs may ascribe to autoimmune pathological responses after inoculated with vaccines. Madhi et al (164) performed a multicenter, double-blind, and a randomized controlled trial and they concluded that a two-dose regimen of AZD1222 vaccination cannot provide sufficient protection for mild-to-moderate COVID-19 subjects against the Beta variant infection.…”

Section: Oxford-astrazeneca Vaccinementioning

confidence: 99%

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

Jiang

Song

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Over the past 2 years, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) and rapidly spread worldwide. In the process of evolution, new mutations of SARS-CoV-2 began to appear to be more adaptable to the diverse changes of various cellular environments and hosts. Generally, the emerging SARS-CoV-2 variants are characterized by high infectivity, augmented virulence, and fast transmissibility, posing a serious threat to the prevention and control of the global epidemic. At present, there is a paucity of effective measurements to cure COVID-19. It is extremely crucial to develop vaccines against SARS-CoV-2 and emerging variants to enhance individual immunity, but it is not yet known whether they are approved by the authority. Therefore, we systematically reviewed the main characteristics of the emerging various variants of SARS-CoV-2, including their distribution, mutations, transmissibility, severity, and susceptibility to immune responses, especially the Delta variant and the new emerging Omicron variant. Furthermore, we overviewed the suitable crowd, the efficacy, and adverse events (AEs) of current vaccines.

show abstract

Onset/flare of psoriasis following the ChAdOx1 nCoV ‐19 Corona virus vaccine ( Oxford‐AstraZeneca /Covishield): Report of two cases

Cited by 26 publications

References 7 publications

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine

Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine

Generalized Pustular Psoriasis Triggered by ChAdOx1nCoV-19 Vaccine: a case report

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

Contact Info

Product

Resources

About